Lymphatic filariasis and onchocerciasis (Q37782466)

23 August 2017

Lymphatic filariasis and onchocerciasis (English)

1 reference

23 August 2017

0 references

0 references

2

Achim Hoerauf

1 reference

23 August 2017

Mark J Taylor

1

1 reference

PubMed ID

20739055

23 August 2017

Moses Bockarie

series ordinal

3

1 reference

PubMed ID

20739055

23 August 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

376

1 reference

23 August 2017

1175-1185

1 reference

23 August 2017

9747

1 reference

Lymphatic filariasis: an infection of childhood

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Meta-analysis of age-prevalence patterns in lymphatic filariasis: no decline in microfilaraemia prevalence in older age groups as predicted by models with acquired immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

River blindness: a success story under threat?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Human infection patterns and heterogeneous exposure in river blindness.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Immunomodulation by filarial nematodes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Alternatively activated and immunoregulatory monocytes in human filarial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Attenuation of toll-like receptor expression and function in latent tuberculosis by coexistent filarial infection with restoration following antifilarial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Human type 1 and 17 responses in latent tuberculosis are modulated by coincident filarial infection through cytotoxic T lymphocyte antigen-4 and programmed death-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Patent filarial infection modulates malaria-specific type 1 cytokine responses in an IL-10-dependent manner in a filaria/malaria-coinfected population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Treatment strategies underpinning the global programme to eliminate lymphatic filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Filariasis and lymphoedema.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The histopathology of bancroftian filariasis revisited: the role of the adult worm in the lymphatic-vessel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Pathogenesis of filarial hydrocele: risk associated with intrascrotal nodules caused by death of adult Wuchereria bancrofti

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Filarial lymphedema is characterized by antigen-specific Th1 and th17 proinflammatory responses and a lack of regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Human bancroftian filariasis: immunological markers of morbidity and infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Aping Jane Goodall: insights into human lymphatic filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

A family study of lymphedema of the leg in a lymphatic filariasis-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Heritable factors play a major role in determining host responses to Wuchereria bancrofti infection in an isolated South Pacific island population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Interdigital skin lesions of the lower limbs among patients with lymphoedema in an area endemic for bancroftian filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Interdigital lesions and frequency of acute dermatolymphangioadenitis in lymphoedema in a filariasis-endemic area.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Clinical and pathological aspects of filarial lymphedema and its management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia bacterial endosymbionts of filarial nematodes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia endosymbiotic bacteria of Brugia malayi mediate macrophage tolerance to TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Human genetic resistance to Onchocerca volvulus: evidence for linkage to chromosome 2p from an autosome-wide scan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia-induced neutrophil activation in a mouse model of ocular onchocerciasis (river blindness).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Toll-like receptor 2 regulates CXC chemokine production and neutrophil recruitment to the cornea in Onchocerca volvulus/Wolbachia-induced keratitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Gamma interferon and interleukin-1 receptor 1 regulate neutrophil recruitment to the corneal stroma in a murine model of Onchocerca volvulus keratitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia endosymbiont levels in severe and mild strains of Onchocerca volvulus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Filaria control and elimination: diagnostic, monitoring and surveillance needs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Diagnostic tools for filariasis elimination programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Assessing transmission of lymphatic filariasis using parasitologic, serologic, and entomologic tools after mass drug administration in American Samoa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

A rapid-format antibody card test for diagnosis of onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

A four-antigen mixture for rapid assessment of Onchocerca volvulus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Mass chemotherapy options to control lymphatic filariasis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Mass treatment to eliminate filariasis in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Ivermectin: uses and impact 20 years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Albendazole for the control and elimination of lymphatic filariasis: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Newly acquired Onchocerca volvulus filariae after doxycycline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

A randomized trial of doxycycline for Mansonella perstans infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Onchocerciasis control: vision for the future from a Ghanian perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Challenges in drug discovery for novel antifilarials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Lymphatic filariasis: Treatment, control and elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Current practices in the management of lymphatic filariasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Lymphatic filariasis elimination programme in India: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The global programme to eliminate lymphatic filariasis: health impact after 8 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Role of vector control in the global program to eliminate lymphatic filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Use of floating layers of polystyrene beads to control populations of the filaria vector Culex quinquefasciatus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Determinants of the eradicability of filarial infections: a conceptual approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Control of onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The Mectizan Donation Program (MDP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

The future of onchocerciasis control in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Final report of the Conference on the eradicability of Onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

What are the mechanisms associated with post-ivermectin serious adverse events?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Evidence against Wolbachia symbiosis in Loa loa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Ivermectin selection on beta-tubulin: evidence in Onchocerca volvulus and Haemonchus contortus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naïve patients from Cameroon, and its relationship with fertility of the worms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

Identifying sub-optimal responses to ivermectin in the treatment of River Blindness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960586-7

7 January 2021

10.1016/S0140-6736(10)60586-7

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20739055